Zorevunersen sodium is an antisense oligonucleotide commercialized by Stoke Therapeutics, with a leading Phase II program in Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy). According to Globaldata, it is involved in 6 clinical trials, of which 1 was completed, 4 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Zorevunersen sodium’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Zorevunersen sodium is expected to reach an annual total of $187 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Zorevunersen sodium Overview
Zorevunersen sodium (STK-001) is under development for the treatment of Dravet syndrome. It is administered via intrathecal route. It is developed based on targeted augmentation of nuclear gene output (TANGO) technology, RNA splicing. The therapeutic candidate increases productive SCN1 mRNA and consequently restore levels of Nav1.1 protein.
Stoke Therapeutics Overview
Stoke Therapeutics is a biotechnology company that develops antisense oligonucleotide which targets RNA splicing to enhance gene expression for the treatment of genetic diseases. The company is developing programs that are in preclinical development for eye and dravet syndrome and central nervous system conditions. Stoke Therapeutics harnesses targeted augmentation of nuclear gene output (TANGO) technology to develop its product portfolio. The company’s pipeline products address the diseases of dgavet syndrome and autosomal dominant optic atrophy. Stoke Therapeutics is headquartered in Bedford, Massachusetts, the US.
The company reported revenues of (US Dollars) US$12.4 million for the fiscal year ended December 2022 (FY2022). The operating loss of the company was US$104.4 million in FY2022, compared to an operating loss of US$86.1 million in FY2021. The net loss of the company was US$101.1 million in FY2022, compared to a net loss of US$85.8 million in FY2021. The company reported negative revenues of US$2.5 million for the second quarter ended June 2023, compared to a revenue of US$5.2 million the previous quarter.
For a complete picture of Zorevunersen sodium’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.